pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant

Abstract

Background:Phosphohistone-H3 (pHH3) is a promising reliable mitotic count biomarker. Our purpose was to study the relationship between the novel proliferation marker pHH3 and the established anti-apoptotic marker survivin and consider their prognostic relevance in endometrial cancer.Methods:A total of 106 patients with endometrial cancer (type I/endometrioid, n=81; type II carcinomas, n=18) and simple hyperplasia without atypia (n=7) were investigated. pHH3 and survivin expression were assessed using immunohistochemistry from paraffin-embedded tissue blocks.Results:A strong positive correlation was observed between pHH3 and survivin expression (P<0.0001). Patients with high-grade tumours and patients with type II carcinomas expressed significantly more pHH3 and survivin than low grade and endometrioid tumours (P<0.0001, P<0.0001, P<0.0001, and P<0.0001, respectively). In univariate survival analysis, overexpression of pHH3 and survivin were associated with increased recurrence and mortality (P<0.0001, P<0.0001, P<0.0001, and P<0.0001, respectively), in the multivariable Cox regression analyses both pHH3 and survivin could be identified as independent parameters for overall survival (P=0.004, and P=0.023, respectively).Conclusion:In endometrial cancer, pHH3 and survivin were strongly positive correlated and were both associated with type II and high-grade tumours. Increasing expression levels of pHH3 and survivin were associated with adverse prognostic factors.

Disrupting Na+,HCO3–-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development

“…39,40 Thus, lower Ki-67 and pHH 3 labeling indices in tumors from NBCn1 KO mice support the implications of NBCn1 inhibition for breast cancer development and progression. Glycolytic conversion of glucose to lactic acid increases with tumor size.…”

Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma

“…In this context, our data are in agreement with those of Ladstein 16 on thick cutaneous melanoma, although in many tumorsincluding melanoma itself-the prognostic value of phospho-histone H3-based mitotic count was found to be stronger than conventional hematoxylin and eosin-based counts. 20,25,37 …”

“…11,12 Phospho-histone H3 immunostaining has been shown to be a reliable and easy method for mitotic index evaluation in melanoma, with both diagnostic [13][14][15][16][17][18] and prognostic 17,[19][20][21] implications. Moreover, it has been also successfully applied in different neoplasms of the breast, [22][23][24][25][26] meninges, [27][28][29] brain, 30 lung, 31 soft tissues, [32][33][34] esophagus, 35 female genital tract, 36,37 prostate, 38 and urothelium, 39 as well as in cytology material from pancreatic endocrine tumors 40 and urothelial carcinoma. 41 The Ki-67 index represents an alternative method for assessing the proliferative potential in adrenocortical tumors and has already been shown to differentiate adrenocortical adenoma from carcinoma, [42][43][44][45][46][47][48][49] and to predict tumor behavior.…”

The mitosis‐specific marker phosphohistone‐H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome‐based study

“…The last issue can be reduced by using PHH3 . In addition to being a practical marker, PHH3 has been shown to be a clinically relevant prognostic indicator in many tumours . The PHH3 score has been shown to predict tumour stage, response to therapy, and/or survival.…”